© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
September 22, 2015
The treatment of TNBC continues to be a challenge for physicians
because of its limited treatment options, the dearth of approved
targeted therapies, high mortality, and poor prognosis.
While TNBC is a heterogeneous group of breast cancers there is
increasing effort to subdivide it into more homogenous groups
that may help in more accurate prognosis and response to therapy.
September 21, 2015
Breast cancer is a leading cause of cancer death in women, with 12% to 20% of cases
classified as triple-negative breast cancer (TNBC).